Table 1 Characteristics of all the studies included in the meta-analysis
Author | Study design | Treatment | Quantity | No. of eyes | Mean age (SD) | Mean BCVA (preintervention) | Mean BCVA (post-intervention) | No. of macular holes | Success rate of macular hole closure | Follow-up period | Total no. of diagnosed VMT cases | VMT release |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kumar et al. [29] | Prospective | PV | – | 15 | 63.8 ± 8.38 | 0.80 ± 0.26 | 0.70 ± 0.49 (20/100 SE) | 15 | 4 (27%) | 3 months | 15 | 12 (80%) |
|  |  | PPV | – | 15 | 68.33 ± 8.19 | 0.904 ± 0.44 | 0.47 ± 0.26 (20/59 SE) | 15 | 15 (100%) | 3 months | 15 | 15 (100%) |
Alreshaid et al. [30] | Retrospective | PPV | – | 11 | Not reported | 0.81 ± 0.24 | 0.64 ± 0.26 | – | – | 10.27 ± 4.63 months | 11 | 11 (100%) |
|  |  | Ocriplasmin | – | 8 | Not reported | 0.53 ± 0.29 | 0.52 ± 0.29 | N/A | N/A | 3.87 ± 2.66 | 8 | 5 (62.5%) |
Anderson et al. [21] | Prospective | PPV | – | 5 | 64.50 | 0.72 ± 0.34 | 0.39 ± 0.20 | 5 | 5 (100%) | 5.5 months | – | – |
|  |  | Ocriplasmin | – | 8 |  | 0.68 ± 0.44 | 0.27 ± 0.16 | 8 | 3 (38%) | 6 months | – | – |
Greven et al. [31] | Retrospective review | Ocriplasmin | – | 51 | 66.9 (19.1) | 0.71 ± 0.35 | 0.83 ± 0.35 | – | – | 1, 3 and 6 months | 51 | 22 (43.1%) |
|  |  | PPV | – | 22 | 69.2 (9.8) | 0.62 ± 0.31 | 0.40 ± 0.23 | – | – | 1, 3 and 6 months | 22 | 22 (100%) |
Juncal et al. [32] | Retrospective case series | Ocriplasmin | 0.125 mg in 0.1 ml | 11 | 68.3 ± 8.74 | 0.56 (20/72 ± 0.28) | 0.28 (20/38 ± 0.16 | 11 | 4 (36.4%) | 12 months | 11 | 4 |
|  |  | PPV | N/A | 11 | 67.8 ± 8.65 | 0.85 (20/140 ± 0.34) | 0.37 (20/47 ± 0.22) | 11 | 10 (90.9%) | 12 months | 11 | 10 |
Nambiar et al. [33] | Retrospective review | Ocriplasmin | 0.125 mg (0.1 mL) | 17 | – | – | – | 17 | 7 | 4 weeks | 17 | 3 (17.6%) |
|  |  | PV | 0.3 cc of 100% C3F8 | 8 | – | – | – | 8 | 4 (50%) |  | 8 | 7 (87.5%) |
Scholz et al. [34] | Retrospective case series | Ocriplasmin | 125 μg | 14 | 73 ± 10 | 82 ± 4 | 81 ± 6 | 1 | 1 (100%) | 4 months | 13 | 7 (50%) |
|  |  | PPV | – | 10 | 68 ± 9 | 78 ± 4 | 80 ± 5 | 5 | 5 (100%) |  | 5 | 5 (100%) |
Steinle et al. [35] | Retrospective | Ocriplasmin | 0.125 mg | 23 | – | – | – | – | – | – | 23 | 48% (11/23) |
|  |  | PV | 0.3 cc of 100% C3F8 gas | 32 | – | – | – | – | – | – | 32 | 84% (27/32) |
Atkins et al. [28] | Retrospective | Ocriplasmin | 0.125 mg | 10 | – | – | 10.34 | – | – | 1 month | 10 | 50% (5) |
|  |  | PV | 0.3 mL of C3F8 gas | 10 | – | – | 0.44 | – | – | 1 month | 10 | 80% (8) |
Yao et al. [36] | Prospective | PPV |  | 87 | 57.78 ± 10.16 | 1.66 | 0.5 ± 0.32 | – | – | 12 months | 87 | 59.8% (52) |